1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Inspira Technologies Oxy B.H.N. Ltd.

Inspira Technologies Oxy B.H.N. Ltd.

IINNW
Inspira Technologies Oxy B.H.N. Ltd.US flagNASDAQ Capital Market
0.14
USD
+0.03
- -
3.41MMarket Cap
Inspira Technologies Oxy B.H.N. Ltd.
IINNW
(NASDAQ Capital Market)

Recent

price

0.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-4,713.84
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-5
-7
-17
-15
-11
-11
-13
-13
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-4,574.39
- -
Profit Margin (%)
- -
-5
- -
20
13
5
3
2
7
Working Capital
- -
- -
- -
1
1
1
- -
- -
1
LT Debt
- -
-5
-2
20
14
6
4
2
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-88.68
-116.54
-219.74
-397.89
-85.25
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
12
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
14
12
9
Cash, Cash Equivalents & STI
7
11
9
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-291.27%
-46.25%
Free Cash Flow
- -
60.98%
4.47%
Net Income, GAAP
- -
23.58%
19.61%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Enovis Corporation (0I1B.L)
PolyNovo Limited (CALZF)
Vapotherm, Inc. (VAPO)
MedX Health Corp (MDXHF)
NeoDynamics AB (publ) (NEOD.ST)
Drägerwerk AG & Co. KGaA (DRWKF)
Business
Inspira Technologies Oxy B.H.N. Ltd. operates as a specialized medical technology company, dedicated to the research, development, and commercialization of advanced respiratory support systems. These innovative solutions are designed to offer less invasive alternatives to traditional mechanical ventilation for patients experiencing acute respiratory distress. The company's core offering, the Inspira ART system, is engineered to quickly elevate and stabilize blood oxygen saturation levels, potentially enabling patients to remain awake throughout treatment. Specifically, the Inspira ART100 system has secured FDA 510(k) clearance for use in cardiopulmonary bypass procedures of limited duration, alongside Israeli AMAR certification for extracorporeal membrane oxygenation and bypass applications. Furthermore, Inspira is actively developing the HYLA blood sensor, a non-invasive device providing continuous, real-time blood parameter monitoring, which recently concluded a successful clinical study with high accuracy and is slated for regulatory submission. Additional pipeline technologies include the Inspira ART500, focused on adaptive blood oxygenation, and the Vortx Oxygen Delivery System, designed to optimize natural blood flow. Recent strategic initiatives, such as the partnership with Westchester Medical Center, aim to evaluate and integrate these advanced systems into clinical care settings. The company was established in 2017 and maintains its headquarters in Ra'anana, Israel.